Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Feb 18:9:858817.
doi: 10.3389/fmed.2022.858817. eCollection 2022.

Editorial: Drug Survival: Treatment of Rheumatic Diseases in the Biologic Era

Lorenzo Di Sanzo  1 , Rossana Scrivo  1 , Enrique Roberto Soriano  2 , Gustavo Citera  3 , Eduardo Mysler  4 , James Cheng-Chung Wei  5 , Mario Humberto Cardiel Ríos  6
Affiliations
Editorial

Editorial: Drug Survival: Treatment of Rheumatic Diseases in the Biologic Era

Lorenzo Di Sanzo et al. Front Med (Lausanne). .
No abstract available

Keywords: arthritis; biologic agents; inflammatory arthropathies; persistence; treatment survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Drug Survival: Treatment of Rheumatic Diseases in the Biologic Era

References

    1. van der Greef J, McBurney RN. Innovation: rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov. (2005) 4:961–7. 10.1038/nrd1904 - DOI - PubMed
    1. Smolen JS, Landewé RB, Bijlsma JW, Burmester GR, Dougados M, Kerschbaumer A, et al. . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. (2020) 79:685–99. 10.1136/annrheumdis-2019-216655 - DOI - PubMed
    1. Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. . EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. (2020) 79:700–12. 10.1136/annrheumdis-2020-218456 - DOI - PMC - PubMed
    1. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, van den Bosch F, Sepriano A, et al. . 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. (2017) 76:978–91. 10.1136/annrheumdis-2016-210770 - DOI - PubMed
    1. Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Hernández-Breijo B, González MA, Monjo I, et al. . The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors. Clin Rheumatol. (2019) 38:949–54. 10.1007/s10067-018-4355-0 - DOI - PubMed

Publication types

LinkOut - more resources